Consensus Immatics N.V.

Stocks

IMTX

NL0015285941

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 16/09/2026 am IST			5-day change	1st Jan Change
8.600 ^USD	-0.23%		-10.04%	-18.10%

25/08	Immatics Announces $150 Million Underwritten Offering	MT
18/08	Immatics' Q2 Net Loss Narrows as Revenue Rises	MT

Evolution of the Average Target: Immatics N.V.

Evolution of the Target Price: Immatics N.V.

Changes in Analyst Recommendations: Immatics N.V.

b27fe341b4e777ad13297adfa98d5._MlE3n4vkLeN3eQZdAqib8HH7_ceH7XTwfwR0tyfN_Y.sZAwmhZ-wMX0lpxeLGX9V6Oiu8JcV8-yjrYj5ajeAbi7hgW4SETV3Li3rQ~d6239fcdde61d17b903808b56ede0ed0

Analysts' recommendations: Immatics N.V.

28/04	TD Cowen Initiates Immatics at Buy	MT
06/03	Deutsche Bank Lifts Price Target on Immatics to $18 From $17, Keeps Buy Rating	MT
07/01	Biotech Sector Poised for Growth Driven by Trial Data, Pharma Deals, BofA Says	MT
06/01	BofA Adjusts Price Target on Immatics to $17 From $14, Maintains Buy Rating	MT
19/11	Mizuho Raises Price Target on Immatics to $23 From $19, Keeps Outperform Rating	MT
18/25/18	Guggenheim Initiates Coverage on Immatics N.V With Buy Rating, $16 Price Target	MT
28/25/28	Deutsche Bank Initiates Coverage on Immatics With Buy Rating, $10 Price Target	MT
07/25/07	BofA Securities Adjusts Price Target on Immatics to $13 From $15, Maintains Buy Rating	MT
07/24/07	Piper Sandler Initiates Immatics With Overweight Rating, $19 Price Target	MT
15/24/15	Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating	MT
02/23/02	Cantor Fitzgerald Initiates Coverage on Immatics with Overweight Rating	MT
18/23/18	Mizuho Ups Price Target on Immatics to $14 From $12, Maintains Buy Rating	MT
31/23/31	Mizuho Initiates Immatics at Buy With $12 Price Target	MT
23/23/23	Chardan Adjusts Price Target on Immatics to $25 From $28, Keeps Buy Rating	MT
10/22/10	Chardan Research Adjusts Price Target on Immatics to $28 From $30, Reiterates Buy Rating	MT
03/22/03	SVB Securities Adjusts Immatics NV's Price Target to $26 from $25, Keeps Outperform Rating	MT
24/22/24	SVB Leerink Adjusts Immatics' Price Target to $25 from $32, Keeps Outperform Rating	MT
14/21/14	SVB Leerink Adjusts Immatics PT to $32 From $28, Maintains Outperform Rating	MT
15/21/15	Immatics N : SVB Leerink Adjusts Immatics NV's Price Target to $27 from $26, Keeps Outperform Rating	MT
18/21/18	Immatics N : Chardan Adjusts Immatics' Price Target to $30 From $28, Reiterates Buy Rating	MT
17/21/17	Immatics N : SVB Leerink Adjusts Immatics NV Price Target to $26 From $17, Maintains Outperform Rating	MT
20/20/20	Immatics N : BofA Securities Starts Immatics at Buy With $13 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	IMMATICS N.V.					+104.56%
	WUXI APPTEC CO., LTD.					+17.76%
	ARGENX SE					+17.76%
	INSMED INCORPORATED					+59.76%
	WUXI BIOLOGICS (CAYMAN) INC.					+18.28%
	BIONTECH SE					+19.67%
	GENMAB A/S					+15.96%
	PHARMAESSENTIA CORPORATION					+17.42%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+28.78%
	SUMMIT THERAPEUTICS INC.					+57.67%
	Average					+35.76%
	Weighted average by Cap.					+25.07%